ABBVIE
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
- Conditions
- Interventions
- First Posted Date
- 2013-01-16
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 96
- Registration Number
- NCT01768858
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 506
- Registration Number
- NCT01760954
A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-09-11
- Last Posted Date
- 2023-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 49
- Registration Number
- NCT01682616
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine /ID# 71593, Chicago, Illinois, United States
🇺🇸North Shore University Hospital /ID# 71813, New Hyde Park, New York, United States
🇦🇺Peter MacCallum Cancer Ctr /ID# 70394, Melbourne, Victoria, Australia
Long-term Study in US Cystic Fibrosis Patients Receiving Digestive Enzyme Supplements to Assess Narrowing of the Large Intestine Causing Adverse Intestinal Symptoms (Fibrosing Colonopathy)
- First Posted Date
- 2012-07-27
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 17
- Registration Number
- NCT01652157
- Locations
- 🇺🇸
Alaska Medical Center /ID# 79256, Anchorage, Alaska, United States
🇺🇸Arkansas Children's Hospital /ID# 79265, Little Rock, Arkansas, United States
🇺🇸University of Arizona Cancer Center - North Campus /ID# 78939, Tucson, Arizona, United States
A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT01594229
- Locations
- 🇺🇸
Johns Hopkins University /ID# 67345, Baltimore, Maryland, United States
🇺🇸Emory University Hospital /ID# 67349, Atlanta, Georgia, United States
🇺🇸Georgia Regents University /ID# 67342, Augusta, Georgia, United States
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
- Conditions
- Interventions
- Drug: BI 655066 (very high i.v. dose)Drug: Placebo, i.v.Drug: Placebo, s.c.Drug: BI 655066 (high s.c. dose)Drug: BI 655066 (low i.v. dose)Drug: BI 655066 (low s.c. dose)Drug: BI 655066 (high medium i.v. dose)Drug: BI 655066 (very low i.v. dose)Drug: BI 655066 (high i.v. dose)Drug: BI 655066 (low medium i.v. dose)
- First Posted Date
- 2012-04-16
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 39
- Registration Number
- NCT01577550
- Locations
- 🇺🇸
1311.1.0007 Boehringer Ingelheim Investigational Site, Burbank, California, United States
🇩🇪1311.1.4901 Boehringer Ingelheim Investigational Site, Berlin, Germany
🇺🇸1311.1.0003 Boehringer Ingelheim Investigational Site, Port Orange, Florida, United States
Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 294
- Registration Number
- NCT01506609
- Locations
- 🇨🇦
Sunnybrook Health Sciences Ctr /ID# 77373, Toronto, Ontario, Canada
🇺🇸The Angeles Clinic and Researc /ID# 60743, Los Angeles, California, United States
🇺🇸University of Pennsylvania /ID# 60753, Philadelphia, Pennsylvania, United States
A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's Disease
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 19
- Registration Number
- NCT01484990
An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2011-08-10
- Last Posted Date
- 2017-11-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 35
- Registration Number
- NCT01413893
Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
- Conditions
- First Posted Date
- 2011-08-08
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 375
- Registration Number
- NCT01412021